Vianautis

ViaNautis Bio to present its targeted polyNaut® nanovesicles (tPNVs) for the generation of in vivo CAR-T therapies at ASGCT Annual Meeting

/in

Targeted polyNaut® nanovesicles (tPNVs) are ViaNautis’ proprietary, polymer-based delivery platform for oligonucleotides enabling cell‑specific targeting through nanobody conjugation CD8 nanobody conjugated tPNVs are simple to manufacture and display high stability at 4°C CD8-tPNVs precisely target CD8-expressing immune cells in vitro and in vivo after intravenous or subcutaneous administration Cambridge, UK – 7 May, 2026  – […]

Read more

Link Biologics strengthens IP position for Link_TSG6 with US patent Notice of Allowance and University of Manchester IP assignment

/in

Secures long‑term ownership and protection of Link_TSG6, strengthening its global IP position in key markets De‑risks development and enhances long‑term value, supporting advancement towards clinical development London, UK – 6 May 2026 – Link Biologics (“Link” or “the Company”), the biotech company developing first-in-class TSG-6-based therapies that have a unique combination of anti-inflammatory, tissue-protective and […]

Read more

Asgard Therapeutics announces oral presentation at ASGCT 2026, showcasing advanced preclinical data on AT-108 – its first-in-class, off-the-shelf, gene-based cancer immunotherapy

/in

AT-108 induces powerful, personalized anti-cancer responses by forcing tumor cells to present their antigens to the immune system Data to be presented at ASGCT 2026 show when used as a monotherapy, AT-108 doubled median survival When used in combination with immune checkpoint blockade (ICB), AT-108 demonstrated strong anti-tumor activity, including significantly extending survival and achieving […]

Read more

Poolbeg Pharma plc – Results for the year ended 31 December 2025

/in

28 April 2026 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces its audited results for the year ended 31 December 2025. Read more…

Read more

Oncoinvent ASA: Annual Report for 2025

/in

Oslo, Norway, 22 April 2026 – Oncoinvent ASA (ONCIN), a biotech company developing a receptor-independent alpha radiopharmaceutical to eradicate cancer cells in the abdominal cavity after surgery with a single, targeted dose, today announced the publication of the Annual Report for 2025. Read more…

Read more
© Optimum Strategic Communications.